Madrigal Pharmaceuticals Appoints Bill Sibold As Chief Executive Officer My Ches Co

Sep 14, 2023•almost 2 years ago

Position

Chief Executive Officer

Company

Madrigal

Bill Sibold

ConshohockenBiotechnologyHealth Care

Description

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. this week announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive Officer and joined Madrigal’s Board of Directors. Dr

Company Information

Company

Madrigal

Location

Conshohocken, Pennsylvania, United States

About

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Madrigal Pharmaceuticals Appoints Bill Sibold As Chief Executive Officer My Ches Co

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Executive Insights

Related People

Ronald hidden

Bill hidden

Mardi hidden

Company Information